FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059143306> ?p ?o ?g. }

• W2059143306 endingPage "1461" @default.
• W2059143306 startingPage "1455" @default.
• W2059143306 abstract "Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University ‘Federico II of Naples’ from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0. Twenty-five patients were recruited. Median age was 65 years (interquartile range 55–74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52%) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96% (range 83.8–98.3%) of the maximum dose intensity that could be delivered. Three patients (12%) presented grade 3–4 neuropathy and ten (40%) presented grade 3–4 neutropenia. Five patients (20%) showed a greater than 50% PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15–24). Median survival was 55 weeks (range 46–64; see Fig. 1). Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings." @default.
• W2059143306 created "2016-06-24" @default.
• W2059143306 creator A5005578190 @default.
• W2059143306 creator A5012423170 @default.
• W2059143306 creator A5013018244 @default.
• W2059143306 creator A5014614796 @default.
• W2059143306 creator A5022468686 @default.
• W2059143306 creator A5024587083 @default.
• W2059143306 creator A5030849745 @default.
• W2059143306 creator A5045829525 @default.
• W2059143306 creator A5060962611 @default.
• W2059143306 creator A5064453022 @default.
• W2059143306 creator A5078562748 @default.
• W2059143306 date "2011-03-02" @default.
• W2059143306 modified "2023-10-08" @default.
• W2059143306 title "Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients" @default.
• W2059143306 cites W1544742800 @default.
• W2059143306 cites W1607353937 @default.
• W2059143306 cites W1848316250 @default.
• W2059143306 cites W1907795058 @default.
• W2059143306 cites W1984749582 @default.
• W2059143306 cites W2015582258 @default.
• W2059143306 cites W2029409133 @default.
• W2059143306 cites W2061196362 @default.
• W2059143306 cites W2103959341 @default.
• W2059143306 cites W2105319126 @default.
• W2059143306 cites W2111199038 @default.
• W2059143306 cites W2123526148 @default.
• W2059143306 cites W2123838638 @default.
• W2059143306 cites W2133489902 @default.
• W2059143306 cites W2139248078 @default.
• W2059143306 cites W2147876556 @default.
• W2059143306 cites W2155679349 @default.
• W2059143306 cites W2158734599 @default.
• W2059143306 cites W2167331614 @default.
• W2059143306 cites W99134297 @default.
• W2059143306 doi "https://doi.org/10.1007/s00280-011-1594-z" @default.
• W2059143306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21365219" @default.
• W2059143306 hasPublicationYear "2011" @default.
• W2059143306 type Work @default.
• W2059143306 sameAs 2059143306 @default.
• W2059143306 citedByCount "23" @default.
• W2059143306 countsByYear W20591433062012 @default.
• W2059143306 countsByYear W20591433062014 @default.
• W2059143306 countsByYear W20591433062016 @default.
• W2059143306 countsByYear W20591433062017 @default.
• W2059143306 countsByYear W20591433062018 @default.
• W2059143306 countsByYear W20591433062019 @default.
• W2059143306 countsByYear W20591433062020 @default.
• W2059143306 countsByYear W20591433062021 @default.
• W2059143306 countsByYear W20591433062022 @default.
• W2059143306 crossrefType "journal-article" @default.
• W2059143306 hasAuthorship W2059143306A5005578190 @default.
• W2059143306 hasAuthorship W2059143306A5012423170 @default.
• W2059143306 hasAuthorship W2059143306A5013018244 @default.
• W2059143306 hasAuthorship W2059143306A5014614796 @default.
• W2059143306 hasAuthorship W2059143306A5022468686 @default.
• W2059143306 hasAuthorship W2059143306A5024587083 @default.
• W2059143306 hasAuthorship W2059143306A5030849745 @default.
• W2059143306 hasAuthorship W2059143306A5045829525 @default.
• W2059143306 hasAuthorship W2059143306A5060962611 @default.
• W2059143306 hasAuthorship W2059143306A5064453022 @default.
• W2059143306 hasAuthorship W2059143306A5078562748 @default.
• W2059143306 hasBestOaLocation W20591433062 @default.
• W2059143306 hasConcept C119060515 @default.
• W2059143306 hasConcept C121608353 @default.
• W2059143306 hasConcept C126322002 @default.
• W2059143306 hasConcept C126894567 @default.
• W2059143306 hasConcept C141071460 @default.
• W2059143306 hasConcept C143998085 @default.
• W2059143306 hasConcept C2776694085 @default.
• W2059143306 hasConcept C2777063308 @default.
• W2059143306 hasConcept C2778720950 @default.
• W2059143306 hasConcept C2780192828 @default.
• W2059143306 hasConcept C2781190966 @default.
• W2059143306 hasConcept C2781413609 @default.
• W2059143306 hasConcept C71924100 @default.
• W2059143306 hasConceptScore W2059143306C119060515 @default.
• W2059143306 hasConceptScore W2059143306C121608353 @default.
• W2059143306 hasConceptScore W2059143306C126322002 @default.
• W2059143306 hasConceptScore W2059143306C126894567 @default.
• W2059143306 hasConceptScore W2059143306C141071460 @default.
• W2059143306 hasConceptScore W2059143306C143998085 @default.
• W2059143306 hasConceptScore W2059143306C2776694085 @default.
• W2059143306 hasConceptScore W2059143306C2777063308 @default.
• W2059143306 hasConceptScore W2059143306C2778720950 @default.
• W2059143306 hasConceptScore W2059143306C2780192828 @default.
• W2059143306 hasConceptScore W2059143306C2781190966 @default.
• W2059143306 hasConceptScore W2059143306C2781413609 @default.
• W2059143306 hasConceptScore W2059143306C71924100 @default.
• W2059143306 hasIssue "6" @default.
• W2059143306 hasLocation W20591433061 @default.
• W2059143306 hasLocation W20591433062 @default.
• W2059143306 hasLocation W20591433063 @default.
• W2059143306 hasLocation W20591433064 @default.
• W2059143306 hasLocation W20591433065 @default.
• W2059143306 hasLocation W20591433066 @default.
• W2059143306 hasOpenAccess W2059143306 @default.

• next